These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 21294474)

  • 61. Immunotherapy of cancer in 2012.
    Kirkwood JM; Butterfield LH; Tarhini AA; Zarour H; Kalinski P; Ferrone S
    CA Cancer J Clin; 2012; 62(5):309-35. PubMed ID: 22576456
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Heat shock proteins and cancer vaccines: developments in the past decade and chaperoning in the decade to come.
    Murshid A; Gong J; Stevenson MA; Calderwood SK
    Expert Rev Vaccines; 2011 Nov; 10(11):1553-68. PubMed ID: 22043955
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Ipilimumab for advanced melanoma: let's not throw caution to the winds.
    Lowe M; Delman KA
    Oncology (Williston Park); 2010 Dec; 24(14):1296, 1299. PubMed ID: 21294473
    [No Abstract]   [Full Text] [Related]  

  • 64. Trial watch: ipilimumab success in melanoma provides boost for cancer immunotherapy.
    Nat Rev Drug Discov; 2010 Aug; 9(8):584. PubMed ID: 20671754
    [No Abstract]   [Full Text] [Related]  

  • 65. CTLA-4-blocking immunotherapy with ipilimumab for advanced melanoma.
    Tarhini AA; Kirkwood JM
    Oncology (Williston Park); 2010 Dec; 24(14):1302, 1304. PubMed ID: 21294474
    [No Abstract]   [Full Text] [Related]  

  • 66. Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010).
    Weber J
    Oncologist; 2008; 13 Suppl 4():16-25. PubMed ID: 19001147
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Ipilimumab: a promising immunotherapy for melanoma.
    Thumar JR; Kluger HM
    Oncology (Williston Park); 2010 Dec; 24(14):1280-8. PubMed ID: 21294471
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy.
    Hoos A; Ibrahim R; Korman A; Abdallah K; Berman D; Shahabi V; Chin K; Canetta R; Humphrey R
    Semin Oncol; 2010 Oct; 37(5):533-46. PubMed ID: 21074069
    [TBL] [Abstract][Full Text] [Related]  

  • 69. CTLA-4 blockade with monoclonal antibodies in patients with metastatic cancer: surgical issues.
    Phan GQ; Weber JS; Sondak VK
    Ann Surg Oncol; 2008 Nov; 15(11):3014-21. PubMed ID: 18716842
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events.
    Weber J
    Oncologist; 2007 Jul; 12(7):864-72. PubMed ID: 17673617
    [TBL] [Abstract][Full Text] [Related]  

  • 71.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 72.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 73.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 74.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 75.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 76.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 77.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 78.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.